New cancer drug AWT020 enters first human trial

NCT ID NCT06092580

Recruiting now Disease control Sponsor: Anwita Biosciences Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial is testing a new biologic drug called AWT020 in 60 adults with advanced solid tumors or lymphoma that have worsened after standard treatments. The main goals are to check the drug's safety at different doses and to see how the body processes it. Participants receive AWT020 by infusion every two weeks or longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AWT020 (a biologic drug given by infusion)
What this could lead to: If this trial shows AWT020 is safe and effective, it could point toward a new treatment option for people with advanced cancers that no longer respond to standard therapies.
What could go wrong: This is a very early (Phase 1/2) and small (60 people) trial, so it is not yet known if AWT020 works or is safe. Many experimental cancer drugs fail in early testing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer hepatocellular carcinoma lymphosarcoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Alfred Health
RECRUITING

Melbourne, Victoria, Australia
ICON Cancer Center South Brisbane
RECRUITING

South Brisbane, Queensland, 4101, Australia
Monash Medical Centre
RECRUITING

Clayton, Victoria, 3168, Australia
Southern Oncology Clinical Research Unit (SOCRU)
RECRUITING

Bedford Park, South Australia, 5042, Australia

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.